YU.A. DOBRESKO^{1, 2}, P.I. PILIPENKO^{1, 2}, L.A. SHCHEPANKEVICH¹

¹Novosibirsk State Medical University, Novosibirsk

²Federal Research Center for Fundamental and Translation Medicine, Novosibirsk

 Contact details:

Dobresko Yu.A. — Assistant Lecturer of the Department of Clinical Neurology and Neurogeriatrics, Junior Researcher at the Laboratory of Clinical and Experimental Neurology

Address: 52 Krasniy prospekt, 2630060 Novosibirsk, Russian Federation, tel.: +7-913-746-19-96, e-mail: dobresko93@inbox.ru

Taxane acute pain syndrome (TAPS) is a clinically significant but understudied side effect. To date, there are few available methods for the prevention and therapeutic treatment of taxane-induced arthralgia and/or myalgia. There is also no data on the true frequency of TAPS.

The purpose — to assess the incidence of TAPS, and to determine whether the occurrence of TAPS early in the cycle may be a predictor of a more severe form of chemo-induced polyneuropathy in patients with breast cancer.

Material and methods. TAPS symptoms were prospectively assessed in 60 patients using the Neurotoxicity Questionnaire (PNQ), the Common Terminology Adverse Event Assessment Criteria Scale (NCI-CTCAE), the McGill Pain Questionnaire (MPQ), and the Cancer Patient General Health Assessment Scale (ECOG) at baseline, 1 week and 13 weeks after the start of chemotherapy.

Results. According to the PNQ questionnaire, 52% of patients treated with taxanes reported the development of arthralgia or myalgia. Arthralgia was observed in 93% of women, and myalgia in 22%. In the group of patients who developed acute pain syndrome after the first administration of taxanes, the severity of chemo-induced peripheral polyneuropathy was higher than in the group where no pain syndrome was observed. The difference was statistically significant both one week (p < 0.05) and 13 weeks (p < 0.05) after the first administration.

Conclusions. The study found that arthralgias and/or myalgias may be common side effects of docetaxel/paclitaxel treatment, and amounted to 52%. We noted that patients with TAPS were more likely to develop peripheral neuropathy after the first administration. More research should be done to better understand the true incidence of TAPS, as well as to determine the optimal therapeutic and preventive treatment methods.

Key words: pain, polyneuropathy, chemotherapy, taxans, breast cancer.

REFERENCES

1. Yared J.A., Tkaczuk K.H. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther, 2012, vol. 6, pp. 371–384.
2. Scripture C.D., Figg W.D., Sparreboom A. Peripheral neuropathy induced by paclitaxel: Recent insights and future perspectives. Curr. Neuropharmacol, 2006, vol. 4, pp. 165–172.
3. Shinde S.S, Seisler D., Soori G., Atherton P.J., Pachman D.R., Lafky J. et al. Can pregabalin prevent paclitaxel-associated neuropathy — an ACCRU pilot trial. Supp. Care Cancer, 2016, vol. 24, pp. 547–553.
4. Chiu N., Zhang L., Dent R. et al. A pro- spective study of docetaxel-associated pain syndrome. Supp. Care Cancer, 2018, vol. 26, pp. 203–211.
5. Fernandes R., Mazzarello S., Hutton B. et al. A systematic review of the incidence and risk factors for taxane acute pain syndrome in patients receiving taxane- based chemotherapy for prostate cancer. Clin. Genitourin Cancer, 2016, vol. 15, pp. 1–6.
6. Chiu N., Chiu L., Chow R., Lam H., Verma S., Pasetka M. et al. Taxane-induced arthralgia and myalgia: a literature review. J. Oncol. Pharm. Pract, 2018, vol. 23, pp. 56–67.
7. Song S.J., Min J., Suh S.Y., Jung S.H., Hahn H.J., Im S.A., Lee J.Y. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Supp. Care Cancer, 2017, vol. 25, pp. 2241–2248.
8. Hellerstedt-Börjesson S., Nordin K., Fjällskog M-L., Holmström I.K., Arving C. Women with breast cancer experience of chemotherapy-induced pain: triangulation of methods. Cancer Nurs, 2015, vol. 38, pp. 31–39.
9. Klinicheskie rekomendatsii. Rak molochnoy zhelezy [Clinical guidelines. Breast cancer], available at https://cr.minzdrav.gov.ru/schema/379_4
10. Hausheer F.H., Schilsky R.L., Bain S., Berghorn E.J., Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin. Oncol, 2006, vol. 33, pp. 15–49.
11. Scripture C.D., Figg W.D., Sparreboom A. Peripheral neuropathy induced by paclitaxel: Recent insights and future perspectives. Curr. Neuropharmacol, 2006, vol. 4, pp. 165–172.
12. Kerckhove N., Collin A., Condé S., Chaleteix C., Pezet D., Balayssac D., Guastella V. Neuropathies périphériques chimio-induite: symptomatologie et épidémiologie [Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology]. Bull. Cancer, 2018, vol. 105, pp. 1020–1032.
13. Toyama T., Yamashita H., Hara Y., Sugiura H., Fujii Y., Iwase H. Biweekly paclitaxel in patients with metastatic breast cancer. Int. J. Clin. Oncol, 2003, vol. 8, pp. 357–361.
14. Saibil S., Fitzgerald B., Freedman O.C. et al. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr. Oncol, 2010, vol. 17, p. 42.
15. Smith R.E., Anderson S.J., Lembersky B.C. et al. Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57. Clin. Breast Cancer, 2014, vol. 5, pp. 208–215.
16. Takabatake D., Taira N., Hara F. et al. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn. J. Clin. Oncol, 2009, vol. 39, pp. 478–483.
17. Smith R.E., Anderson S.J., Brown A. et al. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin. Breast Cancer, 2002, vol. 3, pp. 333–340.
18. Lin Y.C., Chang H.K., Chen J.S. et al. A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn. J. Clin. Oncol, 2007, vol. 37, pp. 23–29.
19. Loprinzi C.L., Maddocks-Christianson K., Wolf S.L., Rao R.D., Dyck P.J.B., Mantyh P., Dyck P.J. The paclitaxel acute pain syn- drome: sensitization of nociceptors as the putative mechanism. Cancer J, 2007, vol. 13, pp. 399–403.
20. Earl H.M., Vallier A.L., Hiller L. et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoad- juvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2 2 factorial randomized phase 3 trial. Lancet Oncol, 2014, vol. 15, pp. 201–212.
21. Lluch A., Ojeba B., Colomer R. et al. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. Cancer, 2000, vol. 89, pp. 2169–2175.
22. Mamounas E.P., Bryant J., Lembersky B. et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol, 2005, vol. 23, pp. 3686–3696.
23. Jones S.E., Savin M.A., Holmes F.A. et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol, 2006, vol. 24, pp. 5381–5387.
24. Bishop J.F., Dewar J., Toner G.C. et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J. Clin. Oncol, 1999, vol. 17, pp. 2355–2364.
25. Dyck P.J., Dyck P.J., Chalk C.H. The 10 P’s: a mnemonic helpful in characterization and differential diagnosis of peripheral neuropathy. Neurology, 1992, vol. 42, pp. 14–18.